HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wyss, M. T. Articles by Buck, A. Search for Related Content PubMed PubMed Citation Articles by Wyss, M. T. Articles by Buck, A.

Uptake of ¹⁸F-Fluorocholine, ¹⁸F-FET, and ¹⁸F-FDG in C6 Gliomas and Correlation with ¹³¹I-SIP(L19), a Marker of Angiogenesis

¹ PET Center, Division of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland; ² Section of Clinical Immunology, University Hospital Zurich, Zurich, Switzerland; ³ Department of Pathology, University Hospital Zurich, Zurich, Switzerland; ⁴ Department of Neurology, University Rostock, Rostock, Germany; ⁵ Department of Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and ⁶ Institute of Pharmacology and Toxicology, University Zurich, Zurich, Switzerland

Correspondence: For correspondence or reprints contact: Alfred Buck, MD, Nuclear Medicine University Hospital, Rämistrasse 100, 8091 Zürich, Switzerland. E-mail: fred.buck{at}usz.ch

Targeting extracellular structures that are involved in angiogenic processes, such as the extra domain B of fibronectin, is a promising approach for the diagnosis of solid tumors. The aim of this study was to determine uptake of the ¹⁸F-labeled PET tracers ¹⁸F-fluorocholine (N,N-dimethyl-N-¹⁸F-fluoromethyl-2-hydroxyethylammonium), ¹⁸F-fluoro-ethyl-L-tyrosine (FET), and ¹⁸F-FDG in C6 gliomas of the rat and to correlate it with uptake of the anti–extra domain B antibody ¹³¹I-SIP(L19) as a marker of neoangiogenesis. Methods: C6 gliomas were orthotopically induced in 17 rats. Uptake of all tracers was measured using quantitative autoradiography, and uptake of ¹⁸F-fluorocholine, ¹⁸F-FET, and ¹⁸F-FDG was correlated with uptake of ¹³¹I-SIP(L19) on a pixelwise basis. Results: The mean ¹³¹I-SIP(L19), ¹⁸F-fluorocholine, ¹⁸F-FET, and ¹⁸F-FDG standardized uptake values in the tumor and the contralateral normal cortex (in parentheses) were 0.31 ± 0.22 (not detectable), 2.00 ± 0.53 (0.49 ± 0.07), 3.67 ± 0.36 (1.42 ± 0.22), and 7.23 ± 1.22 (3.64 ± 0.51), respectively. The ¹³¹I-SIP(L19) uptake pattern correlated best with ¹⁸F-fluorocholine uptake ( = 0.80, averaged -transformed Pearson correlation coefficient) and ¹⁸F-FET uptake ( = 0.79) and least with ¹⁸F-FDG ( = 0.37). Conclusion: One day after intravenous injection, ¹³¹I-SIP(L19) displayed a very high tumor-to-cortex ratio, which may be used in the diagnostic work-up of brain tumor patients. Of the 3 investigated ¹⁸F tracers, ¹⁸F-fluorocholine and ¹⁸F-FET correlated better with the pattern of ¹³¹I-SIP(L19) uptake than did ¹⁸F-FDG. Whether this means that ¹⁸F-fluorocholine and ¹⁸F-FET are better suited than ¹⁸F-FDG to monitor antiangiogenic therapy should be investigated in future studies.

Key Words: extra domain B of fibronectin • angiogenesis • ¹⁸F-fluorocholine • ¹⁸F-fluoro-ethyl-L-tyrosine • ¹⁸F-FDG

^* Contributed equally to this work.

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.